Thermo Fisher Scientific Inc (TMO)

TMO 
$139.12
*  
0.50
0.36%
Get TMO Alerts
*Delayed - data as of Jul. 30, 2015  -  Find a broker to begin trading TMO now
Exchange: NYSE
Industry: Capital Goods
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Thermo Fisher Scientific (TMO)

Q3 2010 Earnings Call

October 27, 2010 8:30 am ET

Executives

Peter Wilver - Chief Financial Officer and Senior Vice President

Kenneth Apicerno - Vice President of Investor Relations and Treasurer

Marc Casper - Chief Executive Officer, President and Director

Analysts

Derik De Bruin - UBS Investment Bank

Sung Ji Nam - JPMorgan

Dan Leonard - First Analysis

Jonathan Groberg - Macquarie Research

Ross Muken - Deutsche Bank AG

Tycho Peterson - JP Morgan Chase & Co

Quintin Lai - Robert W. Baird & Co. Incorporated

Paul Knight - Credit Agricole Securities (USA) Inc.

Marshall Urist - Morgan Stanley

Isaac Ro - Goldman Sachs Group Inc.

Doug Schenkel - Cowen and Company, LLC

Jon Wood - Jefferies & Company, Inc.

Charles Butler - Barclays Capital

Amit Bhalla - Citigroup Inc

Presentation

Operator

Good day, ladies and gentlemen. My name is Carmen, and I'll be your coordinator for today. And welcome to the Thermo Fisher Scientific Third Quarter 2010 Earnings Conference Call. I would now like to introduce our moderator for the call, Mr. Kenneth Apicerno, Vice President, Investor Relations. Mr. Apicerno, you may begin the call.

Kenneth Apicerno

Good morning, and thank you for joining us. On the

call with me today is Marc Casper, our President and Chief Executive Officer; and Pete Wilver, Senior Vice President and Chief Financial Officer. Please note that this call is being webcast live and will be archived on the Investors section of our website, thermofisher.com, under the heading Webcast and Presentations, until Friday, November 26, 2010. A copy of the press release of our third quarter 2010 earnings and future expectations is available on our website under the heading Financial Results.

So before we begin, let me briefly cover our Safe Harbor statement. Various remarks that we may make about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the company's Form 10-Q for the quarter ended July 3, 2010, under the caption Risk Factors, which is on file with the Securities and Exchange Commission and available on the Investors section of our website under the heading SEC Filings.

While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Also during the call, we'll be referring to certain financial measures not prepared in accordance with generally accepted accounting principles, or GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures is available in the press release of our third quarter 2010 earnings and future expectations, and also in the Investors section of our website under the heading Financial Results.

So with that, I'll now turn the call over to Marc.

Marc Casper

Thanks, Ken. Good morning, everyone and thank you

for joining us for our 2010 third quarter earnings call. We're very pleased to report excellent financial results, highlighted by record third quarter EPS performance. As I outlined earlier this year, we are intensely focused on achieving strong EPS growth, and we successfully delivered on that goal again this quarter. We are also pleased to announce that we are raising our EPS and revenue guidance for 2010, which we will discuss later during the call.

Let me begin by reviewing our Q3 results at a high level. As you saw in our press release, adjusted earnings per share grew 50% to our record $0.90 versus $0.78 in the 2009 quarter. I'd like to focus on the three key drivers of our EPS performance. The first, top line revenue growth; the second, operating excellence; and the third, disciplined capital deployment. So let me start with covering top line revenue growth. Revenues for the third quarter increased 6% to $2.68 billion compared with $2.53 billion in the 2009 quarter. Our Analytical Technologies segment contributed significantly to our revenue growth in the quarter. In our Analytical Instruments business, which you may recall had a solid first half, we saw even stronger revenue performance in Q3. In addition, our Clinical Diagnostics and Biosciences businesses continue to report strong growth. In our Laboratory Products and Services segment, sales of equipment and consumables were strong across academic and government, biopharma and industrial end markets.

I'll now turn to our second EPS growth driver, which is operating excellence. Let me start by saying how proud I am of our teams and how they delivered excellent operating performance in the quarter. Their sharp focus on successfully executing on their plans lead to solid Q3 results and positions us well to achieve our goals for the full year.

Our proven operating discipline also gives us the distinct advantage of being able to invest for the future. As we outlined at the beginning of the year, our plans for 2010 included increasing our investment in both technology innovation and emerging markets.

In Q3, we ramped up our R&D spend by 30 basis points year-over-year to expand our pipeline of new technologies. We also increased SG&A expense to continue to build our presence in emerging markets, particularly, Asia. One of the fruits of this investment is our new China Technology Center in Shanghai. This resource is focused on developing products and technologies in China, for China. In other words, specifically geared to the needs of our customers in that important market place.

It's important for me to note, even with these significant investments, we achieved 30 basis points of adjusted operating margin expansion during the quarter. Our excellent operating results are tied largely to a culture of practical processes improvement or PPI, which as you know, is how Thermo Fisher increases productivity to better serve our customers around the world. PPI and PPI Lean will continue to be important contributors to our operating results.

Read the rest of this transcript for free on seekingalpha.com